Patents by Inventor Marc Debelle

Marc Debelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANS-4--N,N-DIMETHYLCARBAMOYL-CYCLOHEXYLAMINE FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
    Publication number: 20150306094
    Abstract: The present invention relates to trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine (cariprazine) and pharmaceutically acceptable salts and hydrates and solvates and polymorphs thereof for use in the treatment of primary negative symptoms of schizophrenia and/or predominantly negative symptoms of schizophrenia.
    Type: Application
    Filed: November 28, 2013
    Publication date: October 29, 2015
    Inventors: János György Pitter, Balázs Szatmári, Marc Debelle, György József Németh, István Laszlovszky
  • BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA
    Publication number: 20110070319
    Abstract: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 24, 2011
    Inventors: Michel BOURIN, Daniel E. Casey, Steven G. Potkin, Mark Rapaport, John Newcomer, Paul P. Yeung, Sangeeta Raje, Jeff Paul, Saeed Ahmed, Luigi M. Barbato, Nathan A. Shapira, Roseline Pardue, Antje A. Winsemius, Michiel H. de Vries, Marc Debelle, Jens Heisterberg, Mette Krog Josiassen, Jette Buch Ostergard, Dorte Malling, Ellen B. Christensen
  • BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA
    Publication number: 20090068290
    Abstract: The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 12, 2009
    Inventors: Michel Bourin, Daniel E. Casey, Steven G. Potkin, Mark Rapaport, John Newcomer, Paul P. Yeung, Sangeeta Raje, Jeff Paul, Saeed Ahmed, Luigi M. Barbato, Nathan A. Shapira, Roseline Pardue, Antje A. Winsemius, Michiel H. de Vries, Marc Debelle, Jens Heisterberg, Mette Krog Josiassen, Jette Buch Ostergard, Dorte Malling, Ellen B. Christensen